Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Mazzeo Laura
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: Zongertinib
Pathologies: Lung cancer
Phase III randomized clinical trial 1:1 of the use of Zongertinib (selective HER2 tyrosine kinase inhibitor) compared to standard reference treatment (IMMUNOTHERAPY) in patients with Non-Small Cell Lung Cancer (NSCLC).
Last update: 13/07/2026